<!DOCTYPE html>
<html lang="zh-Hant" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>巴菲特AI價值投資-輝瑞 2025Q2 財務分析報告</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;500;700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Noto Sans TC', sans-serif;
            background-color: #f8fafc; /* A light gray background */
        }
        /* Custom styles for active navigation link */
        .active-nav-link {
            color: #0ea5e9; /* sky-500 */
            font-weight: 700;
            border-bottom: 2px solid #0ea5e9;
        }
        .inactive-nav-link {
            color: #475569; /* slate-600 */
            border-bottom: 2px solid transparent;
            transition: all 0.3s ease;
        }
        .inactive-nav-link:hover {
            color: #0284c7; /* sky-600 */
        }
        /* Ensure sticky table header has a background */
        .sticky-header th {
            position: sticky;
            top: 0;
            background-color: #f1f5f9; /* slate-100 */
            z-index: 10;
        }
    </style>
</head>
<body class="text-slate-700">

    <!-- Header & Navigation -->
    <header class="bg-white/90 backdrop-blur-lg shadow-md sticky top-0 z-50">
        <nav class="container mx-auto px-6 py-4 flex justify-between items-center">
            <a href="#" class="text-2xl font-bold text-sky-600">
                輝瑞(Pfizer) 2025Q2
            </a>
            <!-- Desktop Menu -->
            <div class="hidden md:flex items-center space-x-6">
                <a href="#overview" class="nav-link inactive-nav-link pb-1">營運概況</a>
                <a href="#strategy" class="nav-link inactive-nav-link pb-1">業務策略</a>
                <a href="#metrics" class="nav-link inactive-nav-link pb-1">營運指標</a>
                <a href="#financials" class="nav-link inactive-nav-link pb-1">財務表現</a>
                <a href="#competition" class="nav-link inactive-nav-link pb-1">競爭分析</a>
                <a href="#risks" class="nav-link inactive-nav-link pb-1">風險因素</a>
                <a href="#recommendation" class="nav-link inactive-nav-link pb-1">綜合評估</a>
            </div>
            <!-- Mobile Menu Button -->
            <div class="md:hidden">
                <button id="mobile-menu-button" class="text-slate-600 focus:outline-none">
                    <svg class="w-6 h-6" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16m-7 6h7"></path></svg>
                </button>
            </div>
        </nav>
        <!-- Mobile Menu -->
        <div id="mobile-menu" class="hidden md:hidden bg-white border-t border-slate-200">
            <a href="#overview" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">公司營運概況</a>
            <a href="#strategy" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">業務策略和發展</a>
            <a href="#metrics" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">營運指標</a>
            <a href="#financials" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">財務表現細節</a>
            <a href="#liquidity" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">投資和流動性</a>
            <a href="#competition" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">產業競爭分析</a>
            <a href="#risks" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">風險和不確定性</a>
            <a href="#guidance" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">關鍵數據匯總及財務指引</a>
            <a href="#recommendation" class="block py-3 px-6 text-slate-600 hover:bg-sky-50">綜合評估及綜合評估</a>
        </div>
    </header>

    <main class="container mx-auto px-6 py-12">

        <!-- 1. 公司營運概況 -->
        <section id="overview" class="mb-16 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">公司營運概況</h2>
            <div class="bg-white rounded-lg shadow-lg p-6 mb-6">
                <p class="text-lg leading-relaxed">輝瑞公司 (Pfizer Inc.) 在 2025 年第二季度展現了強勁的核心業務實力與卓越的營運效率，其表現超出了市場預期。這表明公司在後疫情時代的轉型策略正逐步奏效，非 COVID-19 產品組合的增長動力成為支撐公司未來發展的關鍵基石。</p>
            </div>
            <div class="grid md:grid-cols-2 lg:grid-cols-3 gap-6">
                <div class="bg-sky-100 rounded-lg shadow p-6">
                    <h3 class="font-bold text-lg text-sky-800">Q2 2025 總營收</h3>
                    <p class="text-4xl font-bold text-sky-600 mt-2">$147 億</p>
                    <p class="text-sky-700 mt-1">同比運營增長 10%</p>
                </div>
                <div class="bg-emerald-100 rounded-lg shadow p-6">
                    <h3 class="font-bold text-lg text-emerald-800">Q2 2025 調整後EPS</h3>
                    <p class="text-4xl font-bold text-emerald-600 mt-2">$0.78</p>
                    <p class="text-emerald-700 mt-1">同比增長 30%</p>
                </div>
                <div class="bg-amber-100 rounded-lg shadow p-6">
                    <h3 class="font-bold text-lg text-amber-800">當前股息收益率</h3>
                    <p class="text-4xl font-bold text-amber-600 mt-2">~7.0%</p>
                    <p class="text-amber-700 mt-1">對收益型投資者具吸引力</p>
                </div>
            </div>
        </section>

        <!-- 2. 業務策略和發展 -->
        <section id="strategy" class="mb-16 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">業務策略和發展</h2>
            <div class="grid md:grid-cols-1 lg:grid-cols-2 gap-8">
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-xl font-bold text-stone-700 mb-3">核心業務增長引擎</h3>
                    <p>在市場過度關注 COVID-19 產品營收下滑的同時，輝瑞的核心產品組合正展現出強大的增長動力。心血管產品（如 Eliquis、Vyndaqel）和腫瘤業務（如 Padcev、Lorbrena）成為公司穩健發展的基石。</p>
                </div>
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-xl font-bold text-stone-700 mb-3">Seagen 收購與腫瘤業務轉型</h3>
                    <p>收購 Seagen 的整合效應正在顯現，其抗體藥物複合體 (ADC) 產品組合顯著增強了輝瑞在腫瘤領域的領導地位。Padcev 等產品已成為特定癌症治療的護理標準，市場份額持續擴大。</p>
                </div>
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-xl font-bold text-stone-700 mb-3">研發策略轉變</h3>
                    <p>輝瑞正從高成本的內部研發模式，轉向更靈活、側重於外部創新的混合模式。透過與 3SBio 等公司的策略合作，引進具備重磅潛力的新藥，旨在提升長期研發效率和投資回報。</p>
                </div>
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-xl font-bold text-stone-700 mb-3">成本控制與資本紀律</h3>
                    <p>公司正穩步推進其淨成本節省計畫，目標到 2027 年底實現約 72 億美元的節省。嚴格的成本控制釋放了資本，用於去槓桿化、股東回報及具備增長潛力的業務發展。</p>
                </div>
            </div>
        </section>

        <!-- 3. 營運指標 -->
        <section id="metrics" class="mb-16 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">營運指標：主要產品表現</h2>
            <div class="bg-white rounded-lg shadow-lg p-6">
                <div class="mb-4">
                    <input type="text" id="product-filter" placeholder="篩選產品名稱..." class="w-full md:w-1/3 p-2 border border-slate-300 rounded-md focus:ring-2 focus:ring-sky-500 focus:border-sky-500">
                </div>
                <div class="overflow-x-auto">
                    <table class="w-full text-left border-collapse">
                        <thead class="sticky-header">
                            <tr>
                                <th class="p-3 font-bold uppercase bg-slate-100 text-slate-600 border border-slate-300">產品名稱</th>
                                <th class="p-3 font-bold uppercase bg-slate-100 text-slate-600 border border-slate-300">Q2 2025 營收</th>
                                <th class="p-3 font-bold uppercase bg-slate-100 text-slate-600 border border-slate-300">運營增長率</th>
                                <th class="p-3 font-bold uppercase bg-slate-100 text-slate-600 border border-slate-300">領域</th>
                            </tr>
                        </thead>
                        <tbody id="product-table-body">
                            <!-- Data will be populated by JavaScript -->
                        </tbody>
                    </table>
                </div>
            </div>
        </section>

        <!-- 4. 財務表現細節 -->
        <section id="financials" class="mb-16 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">財務表現細節</h2>
             <div class="bg-white rounded-lg shadow-lg p-6 mb-6">
                <h3 class="text-xl font-bold text-stone-700 mb-4">主要產品 Q2 2025 營收分佈 (十億美元)</h3>
                <div class="relative h-96 w-full">
                    <canvas id="revenueChart"></canvas>
                </div>
            </div>
        </section>

        <!-- 5. 投資和流動性 -->
        <section id="liquidity" class="mb-16 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">投資和流動性</h2>
            <div class="bg-white rounded-lg shadow-lg p-6">
                <ul class="space-y-4 list-disc list-inside text-lg">
                    <li><span class="font-bold">股東回報：</span>2025 年上半年透過股息向股東返還 49 億美元，並強調股息是首要任務。</li>
                    <li><span class="font-bold">去槓桿化：</span>在收購 Seagen 後，去槓桿化進程快於預期，總槓桿率目標從 3.25 倍下調至 2.7 倍。</li>
                    <li><span class="font-bold">業務發展能力：</span>保留了約 130 億美元的業務發展 (BD) 能力，可能用於數筆規模較小的交易，而非大型併購。</li>
                    <li><span class="font-bold">財務紀律：</span>在尋求外部增長機會的同時，保持謹慎的財務姿態，優先考慮資產負債表的健康。</li>
                </ul>
            </div>
        </section>

        <!-- 6. 產業競爭分析 -->
        <section id="competition" class="mb-16 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">產業競爭分析</h2>
            <div class="bg-white rounded-lg shadow-lg p-6">
                <p class="mb-4">輝瑞在營收規模上位居行業頂端，但其市場估值卻遠遠落後於同行。這種估值脫節源於市場對 COVID 營收下滑、專利懸崖和監管風險的過度悲觀，也構成了其價值投資論點的核心。</p>
                <div class="overflow-x-auto">
                    <table class="w-full text-left border-collapse">
                        <thead class="bg-slate-100">
                            <tr>
                                <th class="p-3 font-bold uppercase text-slate-600 border border-slate-300">公司</th>
                                <th class="p-3 font-bold uppercase text-slate-600 border border-slate-300">市值 (十億美元)</th>
                                <th class="p-3 font-bold uppercase text-slate-600 border border-slate-300">預期本益比</th>
                                <th class="p-3 font-bold uppercase text-slate-600 border border-slate-300">股息收益率 (%)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr class="bg-sky-50 font-bold">
                                <td class="p-3 border border-slate-300">輝瑞 (PFE)</td>
                                <td class="p-3 border border-slate-300">~136</td>
                                <td class="p-3 border border-slate-300">~8.0x</td>
                                <td class="p-3 border border-slate-300">~7.0%</td>
                            </tr>
                            <tr>
                                <td class="p-3 border border-slate-300">默克 (MRK)</td>
                                <td class="p-3 border border-slate-300">~200</td>
                                <td class="p-3 border border-slate-300">~8.7x</td>
                                <td class="p-3 border border-slate-300">~3.5%</td>
                            </tr>
                            <tr class="bg-slate-50">
                                <td class="p-3 border border-slate-300">嬌生 (JNJ)</td>
                                <td class="p-3 border border-slate-300">~359</td>
                                <td class="p-3 border border-slate-300">~18.1x</td>
                                <td class="p-3 border border-slate-300">~3.0%</td>
                            </tr>
                             <tr>
                                <td class="p-3 border border-slate-300">禮來 (LLY)</td>
                                <td class="p-3 border border-slate-300">~686</td>
                                <td class="p-3 border border-slate-300">~62.1x</td>
                                <td class="p-3 border border-slate-300">~1.0%</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
        </section>

        <!-- 7. 風險和不確定性 -->
        <section id="risks" class="mb-16 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">風險和不確定性</h2>
            <div class="grid md:grid-cols-1 lg:grid-cols-3 gap-6">
                <div class="bg-white rounded-lg shadow-lg p-6 border-l-4 border-red-500">
                    <h3 class="text-xl font-bold text-red-700 mb-3">專利懸崖 (2026-2028)</h3>
                    <p>Eliquis、Ibrance 和 Xtandi 等三款暢銷產品將面臨專利到期，這是主要的看空論點。公司需要透過新產品線的成功來抵銷營收損失。</p>
                </div>
                <div class="bg-white rounded-lg shadow-lg p-6 border-l-4 border-orange-500">
                    <h3 class="text-xl font-bold text-orange-700 mb-3">地緣政治與政策風險</h3>
                    <p>美國《通膨削減法案》(IRA) 已對藥品淨價產生影響，未來的價格談判和潛在的新貿易政策帶來了巨大的不確定性。</p>
                </div>
                <div class="bg-white rounded-lg shadow-lg p-6 border-l-4 border-yellow-500">
                    <h3 class="text-xl font-bold text-yellow-700 mb-3">競爭與研發執行風險</h3>
                    <p>生物製藥行業競爭激烈，Vyndaqel 和 ADC 領域均面臨強大對手。任何關鍵臨床試驗的失敗都將嚴重損害其長期增長前景。</p>
                </div>
            </div>
        </section>

        <!-- 8. 關鍵數據匯總及財務指引 -->
        <section id="guidance" class="mb-16 scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">關鍵數據匯總及財務指引</h2>
             <div class="grid md:grid-cols-2 gap-6">
                <div class="bg-blue-100 rounded-lg shadow p-6 text-center">
                    <h3 class="font-bold text-xl text-blue-800">2025 全年營收指引</h3>
                    <p class="text-5xl font-bold text-blue-600 mt-3">$610 - $640 億</p>
                </div>
                <div class="bg-indigo-100 rounded-lg shadow p-6 text-center">
                    <h3 class="font-bold text-xl text-indigo-800">2025 全年調整後EPS指引</h3>
                    <p class="text-5xl font-bold text-indigo-600 mt-3">$2.90 - $3.10</p>
                    <p class="text-indigo-700 mt-1">(中位數上調 $0.10)</p>
                </div>
            </div>
        </section>

        <!-- 9. 綜合評估 -->
        <section id="recommendation" class="scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">綜合評估</h2>
            <div class="bg-white rounded-lg shadow-lg p-8">
                <!--<div class="text-center mb-6">
                    <span class="text-2xl font-bold text-white bg-green-600 px-8 py-3 rounded-full shadow-lg">投資建議：買入 (BUY)</span>
                </div>-->
                <p class="text-lg leading-relaxed mb-4">市場對輝瑞給予了過度的折價，過分關注 COVID-19 產品營收下滑及政策風險，而忽略了其穩健的非 COVID 業務、變革性的產品線潛力，以及積極的利潤率擴張計畫。當前約 8.0 倍的預期本益比和約 7% 的股息收益率，為長期價值投資者提供了極具吸引力的安全邊際和回報潛力。</p>
                <div class="mt-6 bg-slate-50 p-6 rounded-lg border border-slate-200">
                    <h4 class="font-bold text-xl text-stone-700 mb-3">適合的投資者畫像：</h4>
                    <ul class="space-y-2 list-disc list-inside">
                        <li>同時重視當前收益的長期價值型投資者。</li>
                        <li>具備 3 到 5 年的投資期限，以等待產品線成熟及估值修復。</li>
                        <li>對政策新聞和產品線挫折相關的風險有中到高的承受能力。</li>
                    </ul>
                </div>
            </div>
        </section>

    </main>

    <footer class="bg-slate-800 text-slate-300 mt-16">
        <div class="container mx-auto px-6 py-4 text-center">
            <p>&copy; 巴菲特AI價值投資-輝瑞 2025Q2 財務分析報告。僅供參考，不構成投資建議。</p>
            <p class="text-xs mt-1">資料來源：基於網路中輝瑞相關公開資料 (2025年8月7日)。</p>
        </div>
    </footer>

    <script>
    document.addEventListener('DOMContentLoaded', function () {
        // --- Mobile Menu Toggle ---
        const mobileMenuButton = document.getElementById('mobile-menu-button');
        const mobileMenu = document.getElementById('mobile-menu');
        mobileMenuButton.addEventListener('click', () => {
            mobileMenu.classList.toggle('hidden');
        });

        // --- Intersection Observer for Active Nav Links ---
        const sections = document.querySelectorAll('section[id]');
        const navLinks = document.querySelectorAll('.nav-link');

        const observerOptions = {
            root: null,
            rootMargin: '0px',
            threshold: 0.4 // 40% of the section must be visible
        };

        const observer = new IntersectionObserver((entries, observer) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    const id = entry.target.getAttribute('id');
                    navLinks.forEach(link => {
                        link.classList.remove('active-nav-link');
                        link.classList.add('inactive-nav-link');
                        if (link.getAttribute('href') === `#${id}`) {
                            link.classList.add('active-nav-link');
                            link.classList.remove('inactive-nav-link');
                        }
                    });
                }
            });
        }, observerOptions);

        sections.forEach(section => {
            observer.observe(section);
        });

        // --- Interactive Product Table ---
        const productData = [
            { name: 'Eliquis (Apixaban)', revenue: '20.0 億', growth: '+6%', category: '心血管' },
            { name: 'Vyndaqel 系列 (Tafamidis)', revenue: '16.0 億', growth: '+21%', category: '心血管' },
            { name: 'Ibrance (Palbociclib)', revenue: '10.5 億', growth: '-8%', category: '腫瘤' },
            { name: 'Xtandi (Enzalutamide)', revenue: '5.66 億', growth: '+14%', category: '腫瘤' },
            { name: 'Padcev (Enfortumab vedotin)', revenue: '5.42 億', growth: '+38%', category: '腫瘤' },
            { name: 'Paxlovid', revenue: '4.27 億', growth: 'N/A', category: 'COVID-19' },
            { name: 'Comirnaty', revenue: '3.81 億', growth: 'N/A', category: 'COVID-19' },
            { name: 'Lorbrena (Lorlatinib)', revenue: '2.51 億', growth: '+48%', category: '腫瘤' },
        ];

        const filterInput = document.getElementById('product-filter');
        const tableBody = document.getElementById('product-table-body');

        function renderTable(data) {
            tableBody.innerHTML = '';
            if (data.length === 0) {
                tableBody.innerHTML = '<tr><td colspan="4" class="text-center p-4 text-slate-500">無符合條件的資料</td></tr>';
                return;
            }
            data.forEach(product => {
                const row = document.createElement('tr');
                row.className = 'hover:bg-slate-50';
                row.innerHTML = `
                    <td class="p-3 border border-slate-200">${product.name}</td>
                    <td class="p-3 border border-slate-200">${product.revenue}</td>
                    <td class="p-3 border border-slate-200 ${product.growth.startsWith('+') ? 'text-green-600' : 'text-red-600'}">${product.growth}</td>
                    <td class="p-3 border border-slate-200">${product.category}</td>
                `;
                tableBody.appendChild(row);
            });
        }

        filterInput.addEventListener('input', (e) => {
            const searchTerm = e.target.value.toLowerCase();
            const filteredData = productData.filter(product => 
                product.name.toLowerCase().includes(searchTerm)
            );
            renderTable(filteredData);
        });

        // Initial render
        renderTable(productData);


        // --- Chart.js Revenue Chart ---
        const ctx = document.getElementById('revenueChart').getContext('2d');
        const chartData = {
            labels: ['Eliquis', 'Vyndaqel', 'Ibrance', 'Xtandi', 'Padcev', 'Paxlovid', 'Comirnaty', 'Lorbrena'],
            datasets: [{
                label: 'Q2 2025 營收 (十億美元)',
                data: [2.0, 1.6, 1.05, 0.566, 0.542, 0.427, 0.381, 0.251],
                backgroundColor: [
                    'rgba(59, 130, 246, 0.7)',
                    'rgba(16, 185, 129, 0.7)',
                    'rgba(234, 179, 8, 0.7)',
                    'rgba(139, 92, 246, 0.7)',
                    'rgba(236, 72, 153, 0.7)',
                    'rgba(249, 115, 22, 0.7)',
                    'rgba(99, 102, 241, 0.7)',
                    'rgba(20, 184, 166, 0.7)'
                ],
                borderColor: [
                    'rgba(59, 130, 246, 1)',
                    'rgba(16, 185, 129, 1)',
                    'rgba(234, 179, 8, 1)',
                    'rgba(139, 92, 246, 1)',
                    'rgba(236, 72, 153, 1)',
                    'rgba(249, 115, 22, 1)',
                    'rgba(99, 102, 241, 1)',
                    'rgba(20, 184, 166, 1)'
                ],
                borderWidth: 1
            }]
        };

        new Chart(ctx, {
            type: 'bar',
            data: chartData,
            options: {
                responsive: true,
                maintainAspectRatio: false,
                plugins: {
                    legend: {
                        display: false
                    },
                    tooltip: {
                        callbacks: {
                            label: function(context) {
                                let label = context.dataset.label || '';
                                if (label) {
                                    label += ': ';
                                }
                                if (context.parsed.y !== null) {
                                    label += '$' + context.parsed.y + ' 億';
                                }
                                return label;
                            }
                        }
                    }
                },
                scales: {
                    y: {
                        beginAtZero: true,
                        title: {
                            display: true,
                            text: '營收 (十億美元)'
                        }
                    }
                }
            }
        });
    });
    </script>
</body>
</html>